Xvivo Perfusion AB (publ) (XVIPY)
Xvivo Perfusion AB (publ) operates in the Medical - Devices industry of the Healthcare sector, headquartered in Gothenburg, SE. The stock last traded at $8.18, up 25.00% on the session, giving a market capitalisation of $1.03B. On trailing twelve-month figures it carries a trailing P/E of 109.32, a net margin of 9.9%. Its beta of 1.76 implies it has historically moved more than the broad market.
Xvivo Perfusion AB (publ), a medical technology enterprise based in Gothenburg, Sweden, specializes in developing cutting-edge solutions for the preservation and perfusion of organs, tissues, and cells, crucial for transplantation. The company's reach spans diverse global markets, including Sweden, the United States, broader North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Its extensive product lineup features the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass system engineered for secure normothermic ex vivo lung perfusion (EVLP). This is supported by the XPS Disposable Lung Kit, which supplies all necessary sterile consumables. Xvivo Perfusion also provides STEEN Solution, a uniquely formulated buffered extracellular solution for perfusing isolated donor lungs during EVLP procedures. Further offerings include Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte preservation solution; the XVIVO Silicone Tubing Set for rapid flushing of donor lungs during the procurement phase; and both the XVIVO LS and XVIVO Disposable Lung Set, specialized devices for EVLP. Additionally, the company offers the XVIVO Organ Chamber, a single-use sterile container designed for the temporary holding of isolated lungs before transplantation into a recipient, alongside the XVIVO Lung Cannula Set, another sterile, single-use disposable product. The company was founded in 1998.
Xvivo Perfusion AB (publ) is most often compared with the following Healthcare names: